Enhancer ID: | E_02_0775 |
Species: | human |
Position : | chr19:34845032-34847032 |
Biosample name: | |
Experiment class : | Low+High throughput |
Enhancer type: | Enhancer |
Disease: | -- |
Pubmed ID: | 29151363 |
Enhancer experiment: | WHG-STARR-seq,ChIP-seq,Luciferase Reporter Assay,ATAC-seq,RNA-seq |
Enhancer experiment description: | In the current study, we use a human prostate cancer cell line, LNCaP as a model to perform whole human genome STARR-seq (WHG-STARR-seq) to reliably obtain an assessment of enhancer activity.Furthermore, these datasets can only identify putative enhancers based on TF and histone chromatin immunoprecipitation (ChIP-seq) data and therefore do not necessarily exhaustively define functional enhancers, leading to false negatives. In order to validate the function of the active enhancers determined by WHG-STARR-seq, we selected 15 regions for all activity measurements and measured their activity using traditional Renilla luciferase reporter assays. |
Target gene : | GPI(AMF,GNPI,NLK,PGI,PHI,SA-36,SA36) |
Strong evidence: | -- |
Less strong evidence: | ATAC-seq,mRNA-seq,WHG-STARR-seq |
Target gene experiment description: | Following treatment with TSA, we performed assay for transposase accessible chromatin sequencing (ATAC-seq) and messenger RNA-sequencing (mRNA-seq) experiments to measure the genome-wide chromatic accessibility and gene expression levels, respectively.Genomic snapshot displaying the GPI locus region as detected by WHG-STARR-seq. There is a strong enhancer region approximately 10 kb upstream of GPI transcriptional start site and another weaker enhancer region in the 3UTR of GPI. |
TF name : | -- |
TF experiment: | -- |
TF experiment description: | -- |
Enhancer function : | -- |
Enhancer function experiment: | -- |
Enhancer function experiment description: |
-- |
SNP ID: | -- |
GeneName | Pathway Name | Source | Gene Number |
---|